How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?

Chest

Volumn 130, Issue 3, 2006, Pages 681-687

  Levine, Robert L ^a   McCollum, David ^b   Hursting, Marcie J ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b CTI Clinical Trial and Consulting Services   (United States)

^c Clinical Science Consulting   (United States)

Author keywords

Adverse effects; Anticoagulant drugs; Heparin; Thrombocytopenia; Thrombosis; Venous thrombosis

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 33748853883     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.3.681     Document Type: Article

References (25)

1. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:401S-428S
2. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia; a critical review. Arch Intern Med 2004; 164:361-369
3. Levine RL, Bursting MJ, Drexler A, et al. Heparin-induced thrombocytopenia in the emergency department. Ann Emerg Med 2004; 44:511-515
4. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:311S-337S
5. Rice L, Attisha WK, Drexler A, et al. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002; 136:210-215
6. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135:502-506
7. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101:502-507
8. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838-1843
9. Leyvraz PR, Bachmann F, Hock J, et al. Prevention of deep vein thrombosis after hip replacement: randomized comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991; 303:543-548
10. Lindhoff-Last E, Nakov R, Misselwitz F, et al. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin. Br J Haematol 2002; 118:1137-1142
11. Macdonald RL, Amidei C, Baron J, et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol 2003; 59:363-374
12. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163:2518-2524
13. Gallus AS, Goodall KT, Tillett J, et al. The relative contributions of antithrombin III during heparin treatment, and clinically recognizable risk factors, to early recurrence of venous thromboembolism. Thromb Res 1987; 46:539-553
14. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with, subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003; 101:2955-2959
15. Kappers-Klunne MC, Boon DMS, Hop WCJ, et al. Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases. Br J Haematol 1997; 96:442-446
16. Schmugge M, Risch L, Huber AR, et al. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 2002; 109:E10-E14
17. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335
18. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991; 114:545-551
19. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140:867-873
20. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695-1702
21. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals. Circulation 1996; 93:2212-2245
22. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia: recommendations of the College of American Pathologists. Arch Pathol Lab Med 2002; 126:1415-1423
23. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation 2005; 111:2671-2683
24. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344:1286-1292
25. Koerber MJ, Smythe MA, Szczesiul J. An evaluation of unfractionated heparin use to assess the magnitude of risk for heparin-induced thrombocytopenia [abstract]. J Thromb Haemost 2005; (3 Suppl 1):P1144